Challenges and Opportunities of a Multi-Institutional Treatment Guideline for Wilms Tumor in Low-Middle-Income Countries-A Report from the Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA).

IF 2.4 3区 医学 Q2 HEMATOLOGY Pediatric Blood & Cancer Pub Date : 2025-02-20 DOI:10.1002/pbc.31616
Patricia Valverde, Thelma Velasquez, Roberta Ortiz, Soad Linneth Fuentes-Alabi, Armando Peña, José Fernando Gonzalez, Tito Luis Gutierrez, Luis Enrique Melendez, Enrique Tome, Magda Arreola, Maria Grazia Valsecchi, Valeria Colombo, Sandra Luna-Fineman, Jessica Blanco-Lopez, Monika L Metzger, Filippo Spreafico
{"title":"Challenges and Opportunities of a Multi-Institutional Treatment Guideline for Wilms Tumor in Low-Middle-Income Countries-A Report from the Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA).","authors":"Patricia Valverde, Thelma Velasquez, Roberta Ortiz, Soad Linneth Fuentes-Alabi, Armando Peña, José Fernando Gonzalez, Tito Luis Gutierrez, Luis Enrique Melendez, Enrique Tome, Magda Arreola, Maria Grazia Valsecchi, Valeria Colombo, Sandra Luna-Fineman, Jessica Blanco-Lopez, Monika L Metzger, Filippo Spreafico","doi":"10.1002/pbc.31616","DOIUrl":null,"url":null,"abstract":"<p><p>Since 2000, centers across Central America have shared treatment guidelines for Wilms tumor, using histology (anaplasia present or absent) and tumor stage to stratify patients into low-, intermediate-, and high-risk groups. Weekly virtual tumor board meetings involving local and international experts were held to ensure consistent treatment assignments. We analyzed data from 367 children with unilateral tumors treated per these guidelines. Five-year abandonment-sensitive event-free and overall survival estimates were: low risk 82% ± 3.8% and 86% ± 3.6%, intermediate risk 50% ± 3.4% and 60% ± 3.4%, and high risk 36% ± 7.6% and 45% ± 7.9%. Survival outcomes were suboptimal, primarily due to advanced disease in fragile children at presentation and abandonment of treatment.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31616"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pbc.31616","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Since 2000, centers across Central America have shared treatment guidelines for Wilms tumor, using histology (anaplasia present or absent) and tumor stage to stratify patients into low-, intermediate-, and high-risk groups. Weekly virtual tumor board meetings involving local and international experts were held to ensure consistent treatment assignments. We analyzed data from 367 children with unilateral tumors treated per these guidelines. Five-year abandonment-sensitive event-free and overall survival estimates were: low risk 82% ± 3.8% and 86% ± 3.6%, intermediate risk 50% ± 3.4% and 60% ± 3.4%, and high risk 36% ± 7.6% and 45% ± 7.9%. Survival outcomes were suboptimal, primarily due to advanced disease in fragile children at presentation and abandonment of treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
自 2000 年以来,中美洲各中心共享了 Wilms 肿瘤的治疗指南,利用组织学(有无增生)和肿瘤分期将患者分为低危、中危和高危组。每周举行一次由当地和国际专家参加的虚拟肿瘤委员会会议,以确保一致的治疗分配。我们分析了根据这些指南治疗的 367 名单侧肿瘤患儿的数据。对放弃敏感的五年无事件生存率和总生存率估计分别为:低风险 82% ± 3.8% 和 86% ± 3.6%,中风险 50% ± 3.4% 和 60% ± 3.4%,高风险 36% ± 7.6% 和 45% ± 7.9%。存活率不理想,主要是由于脆弱儿童发病时病情已到晚期,以及放弃治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pediatric Blood & Cancer
Pediatric Blood & Cancer 医学-小儿科
CiteScore
4.90
自引率
9.40%
发文量
546
审稿时长
1.5 months
期刊介绍: Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.
期刊最新文献
Pediatric Mixed Phenotype Acute Leukemia With ETV6::ARNT Fusion Gene Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation. A Toolkit for Healthcare Transition for Adolescents With Classical Myeloproliferative Neoplasms. A Unique Case of Recurrence After Adjuvant Chemotherapy in Pleuropulmonary Blastoma (PPB) Type I With Transformation to PPB Type III. Azacytidine Monotherapy in an Infant With Mosaic NRAS-Driven Juvenile Myelomonocytic Leukemia. Clival Chordoma Presenting as Airway Obstruction in a Neonate With Tuberous Sclerosis and Good Response to sirolimus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1